ICU Medical (NASDAQ:ICUI - Get Free Report) was upgraded by analysts at Jefferies Financial Group from a "hold" rating to a "buy" rating in a research report issued on Wednesday, Marketbeat.com reports. The brokerage presently has a $200.00 price target on the medical instruments supplier's stock. Jefferies Financial Group's target price indicates a potential upside of 20.34% from the stock's current price.
Several other analysts have also weighed in on the stock. StockNews.com upgraded shares of ICU Medical from a "hold" rating to a "buy" rating in a research report on Wednesday, November 20th. Raymond James upped their price objective on ICU Medical from $158.00 to $190.00 and gave the company an "outperform" rating in a research note on Thursday, September 12th. KeyCorp increased their target price on ICU Medical from $198.00 to $209.00 and gave the stock an "overweight" rating in a report on Wednesday, November 13th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of ICU Medical in a research note on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, ICU Medical has an average rating of "Moderate Buy" and a consensus target price of $177.25.
Read Our Latest Stock Analysis on ICUI
ICU Medical Stock Performance
ICUI traded up $6.08 on Wednesday, hitting $166.19. 308,089 shares of the stock traded hands, compared to its average volume of 271,797. The business has a fifty day moving average price of $171.99 and a two-hundred day moving average price of $150.34. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. ICU Medical has a 52 week low of $83.26 and a 52 week high of $196.26. The firm has a market capitalization of $4.07 billion, a PE ratio of -35.03 and a beta of 0.62.
Insider Buying and Selling
In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the company's stock in a transaction on Friday, November 1st. The stock was sold at an average price of $171.84, for a total transaction of $2,062,080.00. Following the transaction, the chief executive officer now owns 104,593 shares of the company's stock, valued at approximately $17,973,261.12. This represents a 10.29 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Christian B. Voigtlander sold 1,962 shares of ICU Medical stock in a transaction on Monday, November 25th. The shares were sold at an average price of $169.08, for a total value of $331,734.96. The disclosure for this sale can be found here. Insiders have sold a total of 40,364 shares of company stock worth $6,869,878 in the last three months. Insiders own 6.70% of the company's stock.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. Hexagon Capital Partners LLC raised its stake in shares of ICU Medical by 162.7% during the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier's stock worth $36,000 after buying an additional 122 shares during the last quarter. Allworth Financial LP raised its position in shares of ICU Medical by 100.0% during the 3rd quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier's stock valued at $36,000 after acquiring an additional 100 shares during the last quarter. Innealta Capital LLC acquired a new position in shares of ICU Medical in the 2nd quarter valued at $32,000. Venturi Wealth Management LLC boosted its position in shares of ICU Medical by 1,510.0% in the 3rd quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier's stock worth $59,000 after purchasing an additional 302 shares during the last quarter. Finally, Point72 Hong Kong Ltd acquired a new stake in shares of ICU Medical during the third quarter worth $72,000. 96.10% of the stock is currently owned by institutional investors and hedge funds.
About ICU Medical
(
Get Free Report)
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
Featured Articles
Before you consider ICU Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICU Medical wasn't on the list.
While ICU Medical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
